US · Healthcare · Biotechnology
EPS came in at -0.84 against a street estimate of -0.62 — a miss of 35.5%.
Analysts rate BridgeBio Pharma Inc a buy (16 buy, 3 hold, 0 sell out of 19) with an average price target of $105.26.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.25% |
| Kohlberg Kravis Roberts & Co LP | 6.76% |
| HHG PLC | 6.72% |
| Viking Global Investors LP | 6.04% |
| Farallon Capital Management, L.L.C. | 4.78% |
| Vanguard Portfolio Management, LLC | 4.12% |
| Vanguard Capital Management, LLC | 3.96% |
| Aisling Capital Management LP | 2.60% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-22 |
| Material agreement · Q3 2026 | 2026-07-02 |
| Board / officer change · Q2 2026 | 2026-06-26 |
| Company announcement · Q2 2026 | 2026-05-27 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-10-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Strategic investment agreement with Sixth Street and KKR affiliates for $933.9M BridgeBio Pharma raised $933.9 million by selling preferred stock to two investors: Sixth Street Partners ($800M for 800,000 shares) and KKR-affiliated HCRx ($133.9M for 133,900 shares). Eac | 2026-07-02 |
| Board approves $500 million stock repurchase program BridgeBio Pharma reported Q1 2026 financial results on May 7, 2026. The 8-K filing itself does not contain specific financial figures or operational details—those are referenced in an attach | 2026-05-07 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BridgeBio Pharma Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.